2/11
04:48 pm
rprx
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/11
04:48 pm
rprx
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions [Seeking Alpha]
Low
Report
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions [Seeking Alpha]
2/11
10:03 am
rprx
Royalty Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Royalty Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
2/11
08:16 am
rprx
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings [Yahoo! Finance]
Low
Report
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings [Yahoo! Finance]
2/11
07:38 am
rprx
Royalty Pharma: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Royalty Pharma: Q4 Earnings Snapshot [Yahoo! Finance]
2/11
07:12 am
rprx
Royalty Pharma reports Q4 results [Seeking Alpha]
Low
Report
Royalty Pharma reports Q4 results [Seeking Alpha]
2/11
07:00 am
rprx
Royalty Pharma Reports Q4 and Full Year 2025 Results
Low
Report
Royalty Pharma Reports Q4 and Full Year 2025 Results
2/10
07:02 am
rprx
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here's Why [Yahoo! Finance]
Low
Report
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here's Why [Yahoo! Finance]
2/1
07:03 pm
rprx
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain [Yahoo! Finance]
Low
Report
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain [Yahoo! Finance]
1/30
06:01 am
rprx
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
Low
Report
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
1/28
10:48 am
rprx
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]
Low
Report
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]
1/27
07:19 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
1/24
07:06 am
rprx
Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]
Low
Report
Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]
1/22
08:11 pm
rprx
Lightning Round: Coherent is a winner, says Jim Cramer [CNBC]
Low
Report
Lightning Round: Coherent is a winner, says Jim Cramer [CNBC]
1/20
04:15 pm
rprx
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Low
Report
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
1/14
08:18 am
rprx
Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]
Low
Report
Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]
1/13
06:33 am
rprx
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
Low
Report
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
1/12
07:15 am
rprx
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/12
01:38 am
rprx
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]
Low
Report
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]
1/11
05:15 pm
rprx
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Low
Report
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
1/9
08:30 am
rprx
Royalty Pharma Announces Dividend Increase
Low
Report
Royalty Pharma Announces Dividend Increase
1/8
11:51 pm
rprx
Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
Low
Report
Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
12/29
08:21 pm
rprx
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]
Low
Report
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]
12/29
04:40 pm
rprx
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Low
Report
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
12/16
08:08 am
rprx
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]
Medium
Report
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]